NeoMatrix Therapeutics

Neo Matrix Therapeutics

Biotechnology, Skyview Ln, Stony Brook University, , 80021, New York, 11920, United States, 1-10 Employees

neomatrixtx.com

  • LinkedIn

Who is NEOMATRIX THERAPEUTICS

NeoMatrix Therapeutics is a clinical-stage company dedicated to developing novel, bioactive peptides that prevent injury progression and thereby rescue tissue and speed healing. Our lead ...

Read More

map
  • 11920 Skyview Ln, Stony Brook University, New York, 80021, United States Headquarters: 11920 Skyview Ln, Stony Brook University, New York, 80021, United States
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 8731

checked-icon Does something look wrong? Fix it. | View contact records from NEOMATRIX THERAPEUTICS

NeoMatrix Therapeutics Org Chart and Mapping

Employees

Fubao Lin

Chief Scientific Officer

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding NeoMatrix Therapeutics

Answer: NeoMatrix Therapeutics's headquarters are located at Skyview Ln, Stony Brook University, , 80021, New York, 11920, United States

Answer: NeoMatrix Therapeutics's official website is https://neomatrixtx.com

Answer: NeoMatrix Therapeutics's revenue is Under $1 Million

Answer: NeoMatrix Therapeutics's SIC: 8731

Answer: NeoMatrix Therapeutics has 1-10 employees

Answer: NeoMatrix Therapeutics is in Biotechnology

Answer: NeoMatrix Therapeutics contact info: Phone number: Website: https://neomatrixtx.com

Answer: NeoMatrix Therapeutics is a clinical-stage company dedicated to developing novel, bioactive peptides that prevent injury progression and thereby rescue tissue and speed healing. Our lead candidates focus on the treatment of severe burns and have the potential to significantly improve the quality of life and clinical outcomes of burn patients by limiting injury progression following the initial burn. This shortens healing time and reduces scarring. Continuing tissue destruction following an initial injury is a problematic phenomenon that occurs in many types of conditions, giving our novel peptides the potential to be used in multiple settings other than burns.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access